This HTML5 document contains 49 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n13http://localhost/temp/predkladatel/
n15http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n12http://linked.opendata.cz/ontology/domain/vavai/
n10http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00216224%3A14110%2F14%3A00078690%21RIV15-MSM-14110___/
shttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
n3http://linked.opendata.cz/ontology/domain/vavai/riv/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n8http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n17http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n11http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n5http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n9http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n7http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n16http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00216224%3A14110%2F14%3A00078690%21RIV15-MSM-14110___
rdf:type
skos:Concept n12:Vysledek
dcterms:description
The aim of the present study was to describe treatment outcomes for bevacizumab in combination with chemotherapy based on data from the Czech registry of targeted therapies for metastatic colorectal cancer (mCRC). Patients and Methods: In total, 4,487 patients with mCRC who received bevacizumab combined with chemotherapy in first line (n=3,990, 88.9%), second line (n=386, 8.6%), or third/higher line (n=111, 25%) had evaluable data and were included in the present retrospective analysis. Results: The median progression-free survival (PFS) was 11.3 months (95% conficence interval [CI]=11.0-11.7 months), 9.5 months (95% CI=8.2-10.9 months), and 7.3 months (95% CI=5.9-8.7 months; p<0.001), and the median overall survival from the start of bevacizumab-containing therapy was 28.4 months (95% CI=27.1-29.8 months), 25.9 months (95% CI=19.4-32.4 months), and 15.0 months (95% CI=10.7-19.3 months; p<0.001), respectively. The aim of the present study was to describe treatment outcomes for bevacizumab in combination with chemotherapy based on data from the Czech registry of targeted therapies for metastatic colorectal cancer (mCRC). Patients and Methods: In total, 4,487 patients with mCRC who received bevacizumab combined with chemotherapy in first line (n=3,990, 88.9%), second line (n=386, 8.6%), or third/higher line (n=111, 25%) had evaluable data and were included in the present retrospective analysis. Results: The median progression-free survival (PFS) was 11.3 months (95% conficence interval [CI]=11.0-11.7 months), 9.5 months (95% CI=8.2-10.9 months), and 7.3 months (95% CI=5.9-8.7 months; p<0.001), and the median overall survival from the start of bevacizumab-containing therapy was 28.4 months (95% CI=27.1-29.8 months), 25.9 months (95% CI=19.4-32.4 months), and 15.0 months (95% CI=10.7-19.3 months; p<0.001), respectively.
dcterms:title
Efficacy and Toxicity of Bevacizumab on Combination with Chemotherapy in Different Lines of Treatment for Metastatic Colorectal Carcinoma Efficacy and Toxicity of Bevacizumab on Combination with Chemotherapy in Different Lines of Treatment for Metastatic Colorectal Carcinoma
skos:prefLabel
Efficacy and Toxicity of Bevacizumab on Combination with Chemotherapy in Different Lines of Treatment for Metastatic Colorectal Carcinoma Efficacy and Toxicity of Bevacizumab on Combination with Chemotherapy in Different Lines of Treatment for Metastatic Colorectal Carcinoma
skos:notation
RIV/00216224:14110/14:00078690!RIV15-MSM-14110___
n3:aktivita
n5:V n5:I n5:N
n3:aktivity
I, N, V
n3:cisloPeriodika
2
n3:dodaniDat
n16:2015
n3:domaciTvurceVysledku
n15:9067094 n15:4504135
n3:druhVysledku
n7:J
n3:duvernostUdaju
n17:S
n3:entitaPredkladatele
n10:predkladatel
n3:idSjednocenehoVysledku
13813
n3:idVysledku
RIV/00216224:14110/14:00078690
n3:jazykVysledku
n11:eng
n3:klicovaSlova
Colorectal cancer; metastasis; bevacizumab; chemotherapy; survival
n3:klicoveSlovo
n8:chemotherapy n8:metastasis n8:survival n8:Colorectal%20cancer n8:bevacizumab
n3:kodStatuVydavatele
GR - Řecká republika
n3:kontrolniKodProRIV
[A85279090B0F]
n3:nazevZdroje
Anticancer Research
n3:obor
n9:FD
n3:pocetDomacichTvurcuVysledku
2
n3:pocetTvurcuVysledku
8
n3:rokUplatneniVysledku
n16:2014
n3:svazekPeriodika
34
n3:tvurceVysledku
Buchler, Tomas Halamkova, Jana Kiss, Igor Melichar, Bohuslav Poprach, Alexander Vyzula, Rostislav Dušek, Ladislav Bortlíček, Zbyněk
n3:wos
000331497200056
s:issn
0250-7005
s:numberOfPages
6
n13:organizacniJednotka
14110